Clinical trial
Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide: A Retrospective Study of the LMC Diabetes Registry
NCT07889453 is registered in ClinicalTrials.gov with LMC Diabetes & Endocrinology Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide: A Retrospective Study of the LMC Diabetes Registry
- Lead sponsor
- LMC Diabetes & Endocrinology Ltd.
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- October 15, 2026
- Completion date
- June 30, 2027
- Enrollment
- 650 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
obesity, type 2 diabetes (t2d)
Arms
As registered; 3 arms.
-
T2D Switch TZP Cohort
adults living with T2D who switched from injectable semaglutide to tirzepatide
-
Obesity Switch TZP Cohort
adults living with obesity without diabetes, who switched from injectable semaglutide and to tirzepatide
-
T2D SEMA Cohort
adults living with T2D who were prescribed injectable semaglutide and did not switch to tirzepatide
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Change from Baseline in Body Weight at 12 Months - T2D Switch TZP Cohort
Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with T2D who switched from injectable semaglutide to tirzepatide during the index period.
-
Change from Baseline in Body Weight at 12 Months - Obesity Switch TZP Cohort
Change in body weight (kg) at 6-12-month follow-up (closest observation to 12 month follow-up, ±6 weeks) compared to baseline (closest observation to the index date, ±6 weeks) among individuals living with obesity (non-diabetes) who switched from injectable semaglutide to tirzepatide during the index period.
Lead sponsor's other trials
LMC Diabetes & Endocrinology Ltd., most recent start first.
+16 more trials See the organization page
Similar trials
Same condition (Diabetes Mellitus, Type 2) and phase, most recent start first.
+1,735 more trials See the condition page